On the stock market since 2025, it operates in the world of consumer spending. It has 13 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 168% a year over the last 3 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades 26% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 168% a year on average.
Sales run at $3.4M a year. A small number, but proof the product has real buyers.
A loss of $1.9M against $3.4M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, PFAI sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: PFAI is a high-risk stock — not yet profitable, and its future rides on its product catching on.